Clinical trial
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy…
NCT00129935 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00129935 |
|---|---|
| Title | EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer |
| Official title | Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment, Node Positive Breast Cancer Patients |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Sanofi Industry Hoffmann-La Roche Pfizer |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine, Epirubicin, Cyclophosphamide |
| Enrollment | 1,384 |
| Start date | Feb 1, 2004 |
| Primary completion | Jun 1, 2013 |
| Completion | Apr 4, 2019 |
| First posted | Aug 12, 2005 |
| Last update posted | Mar 31, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: